Drug Profile
Sacrosidase - QOL Medical
Alternative Names: SucraidLatest Information Update: 31 Jan 2023
Price :
$50
*
At a glance
- Originator Hartford Hospital
- Developer QOL Medical
- Class Glycoside hydrolases
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Sucrase-isomaltase deficiency
Most Recent Events
- 27 Jan 2023 QOL Medical plans a phase II trial for Fructan intolerance in February 2023 (NCT05703009)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Sucrase-isomaltase-deficiency in Canada (PO, Liquid)
- 29 Nov 2011 Sacrosidase licensed to Medunik Canada in Canada